Nerviano Medical Sciences S.r.l. Announces Collaboration and Option to License Agreement with Merck

Nerviano Medical Sciences S.r.l. (NMS), a member of the NMS Group and a clinical stage company discovering and developing innovative therapies for the treatment of cancer, announced today the signing of a collaboration agreement with licensing option with Merck Healthcare KGaA (Merck), for the next-generation highly selective and brain penetrant PARP1 inhibitor NMS-293.

PARP (poly (ADP-ribose) polymerase) is key in the repair of DNA damage and PARP inhibitors have been shown to be highly effi…


– 출처 : https://www.newswire.co.kr/newsRead.php?no=951850&sourceType=rss

함께 보면 좋은 콘텐츠